Clinical Trial Update: Sitagliptin Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease [Phase 4]

View source ↗

Summary

A Phase 4 trial reports that sitagliptin reduces left ventricular mass in normotensive patients with type 2 diabetes and coronary artery disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• Sitagliptin (Januvia) (sitagliptin)

Snippet

Sponsor: Wuhan General Hospital of Guangzhou Military Command | Conditions: Newly Diagnosed Type 2 Diabetes, Coronary Artery Disease | Phase 4 | Status: COMPLETED